Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

Leading orphan drugs in development based on net present value 2020

This statistic displays a projection of the top 10 orphan R&D products (phase III/filed) by net present value as of 2020. Ide-Cel had a net present value of 6.2 billion U.S. dollars. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.

Projection of top 10 orphan drugs in development (phase III/filed) by NPV as of 2020

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

April 2020

Region

Worldwide

Survey time period

as of February 2020

Supplementary notes

NPV: net present value

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Orphan drugs"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.